CRISPR/Cas9 Gene-Edited Hematopoietic Stem Cell Therapy for Sickle Cell Disease
Vionnie W.C. Yu(St. Jude Children's Research Hospital), Susan C. Stevenson(Clinical Trial Investigators), Jessica Seitzer(Intellia Therapeutics (United States)), Jennifer L. Snead(Oregon Health & Science University), William R. Tschantz, Yanick Mulumba(Intellia Therapeutics (United States)), Lisa Quinn, Kevin L. Sloan(Intellia Therapeutics (United States)), Victor Guosheng Lin(Novartis (Switzerland)), Craig Mickanin, Matthew Curran(Novartis (Switzerland)), Walter Strapps, Reynald Lescarbeau(Tufts University), Lloyd B. Klickstein(William James College), Christian Schmedt(Genomics Institute of the Novartis Research Foundation), Amy Janiak(Novartis (Switzerland)), Yi Liu(Ningbo University), Pu Zhang(Macau University of Science and Technology), Yi Yang(Novartis (Switzerland)), Morag Stewart(Intellia Therapeutics (United States)), Carsten Russ(Broad Institute), Hon-Ren Huang(Intellia Therapeutics (United States)), Brad Murray(Intellia Therapeutics (United States)), Scott Clarkson
Cited by 6
Related Papers
A Draft Sequence of the Neandertal Genome
|Science|2010|4.6k
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing
|Nature Biotechnology|2009|1.5k
Analyzing and minimizing PCR amplification bias in Illumina sequencing libraries
|Genome biology|2011|1.2k